IL256523A - Compositions and methods for treating cancer - Google Patents
Compositions and methods for treating cancerInfo
- Publication number
- IL256523A IL256523A IL256523A IL25652317A IL256523A IL 256523 A IL256523 A IL 256523A IL 256523 A IL256523 A IL 256523A IL 25652317 A IL25652317 A IL 25652317A IL 256523 A IL256523 A IL 256523A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562183517P | 2015-06-23 | 2015-06-23 | |
| PCT/US2016/039022 WO2016210134A1 (en) | 2015-06-23 | 2016-06-23 | Compositions and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL256523A true IL256523A (en) | 2018-02-28 |
Family
ID=57586472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL256523A IL256523A (en) | 2015-06-23 | 2017-12-24 | Compositions and methods for treating cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10744141B2 (enExample) |
| EP (1) | EP3313819A1 (enExample) |
| JP (1) | JP2018518522A (enExample) |
| CN (1) | CN108779073A (enExample) |
| AU (1) | AU2016281646A1 (enExample) |
| CA (1) | CA2990835A1 (enExample) |
| IL (1) | IL256523A (enExample) |
| WO (1) | WO2016210134A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2999177A1 (en) | 2015-09-24 | 2017-03-30 | The Regents Of The University Of California | Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021188949A1 (en) * | 2020-03-20 | 2021-09-23 | Atux Iskay Llc | 3-diarylmethylenes and uses thereof |
| WO2021202780A2 (en) * | 2020-04-01 | 2021-10-07 | Engine Biosciences Pte. Ltd. | Methods and compositions for treating cancer |
| WO2022094615A1 (en) * | 2020-10-29 | 2022-05-05 | The Regents Of The University Of California | Compounds and methods for increased antisense activity |
| CN114617969B (zh) * | 2020-12-14 | 2023-08-25 | 上海市肿瘤研究所 | 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用 |
| JP2024508687A (ja) * | 2021-02-08 | 2024-02-28 | ラプタ セラピューティクス オーワイ | プロテインホスファターゼ２ａ（ｐｐ２ａ）の置換環状調節物質およびこれを用いた方法 |
| CN112816453B (zh) * | 2021-02-09 | 2022-07-08 | 黑龙江大学 | 蛋白在预测药物性能上的应用 |
| CN113616795B (zh) * | 2021-08-31 | 2023-06-20 | 上海交通大学医学院附属瑞金医院 | Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍 |
| CN114984221A (zh) * | 2022-05-25 | 2022-09-02 | 浙江大学 | Pp2a及其激活剂在急性缺血性脑卒中制药、标记的应用 |
| CN116421726A (zh) * | 2023-04-14 | 2023-07-14 | 中国海洋大学 | 一种基于分子预测的靶向plk1纳米药物的开发方法 |
| WO2025230951A1 (en) * | 2024-04-29 | 2025-11-06 | Icahn School Of Medicine At Mount Sinai | Method of treating adenoid cystic carcinoma |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045515A1 (en) * | 2001-05-24 | 2003-03-06 | Lise Binderup | Combination medicament for treatment of neoplastic diseases |
| EP1996193A2 (en) * | 2006-03-13 | 2008-12-03 | OSI Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| US20090020197A1 (en) * | 2007-07-16 | 2009-01-22 | Key Safety Systems, Inc. | Gas generating compositions and airbag inflators |
| WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
| WO2009117769A1 (en) * | 2008-03-25 | 2009-10-01 | Newcastle Innovation Limited | Inhibition of c-kit cancers |
| WO2010120711A1 (en) * | 2009-04-13 | 2010-10-21 | The Ohio State University Research Foundation | Protein phosphatase 2a-activating agents |
| US9134297B2 (en) * | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| HK1198384A1 (en) * | 2011-08-16 | 2015-04-17 | Mt. Sinai School Of Medicine | Tricyclic compounds as anticancer agents |
| JP2015500885A (ja) * | 2011-12-22 | 2015-01-08 | スレッショルド ファーマシューティカルズ，インコーポレイテッド | 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 |
| US20140357573A1 (en) * | 2013-03-15 | 2014-12-04 | Life Technologies Corporation | Prognostic assay for squamous cell lung carcinoma |
| WO2015138496A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Constrained tricyclic sulfonamides |
| US9937186B2 (en) | 2014-03-11 | 2018-04-10 | Icahn School Of Medicine At Mount Sinai | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents |
-
2016
- 2016-06-23 EP EP16815302.1A patent/EP3313819A1/en not_active Withdrawn
- 2016-06-23 CN CN201680044840.5A patent/CN108779073A/zh active Pending
- 2016-06-23 CA CA2990835A patent/CA2990835A1/en not_active Abandoned
- 2016-06-23 JP JP2017567214A patent/JP2018518522A/ja active Pending
- 2016-06-23 WO PCT/US2016/039022 patent/WO2016210134A1/en not_active Ceased
- 2016-06-23 US US15/738,870 patent/US10744141B2/en active Active
- 2016-06-23 AU AU2016281646A patent/AU2016281646A1/en not_active Abandoned
-
2017
- 2017-12-24 IL IL256523A patent/IL256523A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10744141B2 (en) | 2020-08-18 |
| CN108779073A (zh) | 2018-11-09 |
| JP2018518522A (ja) | 2018-07-12 |
| US20180185382A1 (en) | 2018-07-05 |
| AU2016281646A1 (en) | 2018-02-01 |
| EP3313819A1 (en) | 2018-05-02 |
| WO2016210134A1 (en) | 2016-12-29 |
| CA2990835A1 (en) | 2016-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304820A (en) | Preparations and methods for the treatment of cancer | |
| AU2022231657A1 (en) | Compositions and Methods for Treating Cancer | |
| IL267247B (en) | Compositions and methods for treating cancer | |
| IL266053A (en) | Preparations and methods for the treatment of ezh2-mediated cancer | |
| IL264034A (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| IL252610A0 (en) | Methods and preparations for the treatment of cancer | |
| SG11201708861VA (en) | Methods for treating cancer | |
| SG11201700079VA (en) | Combination therapy compositions and methods for treating cancers | |
| SMT202200370T1 (it) | Composizione per il trattamento del cancro | |
| IL254710A0 (en) | Compositions and methods for treating anemia | |
| PT3200815T (pt) | Métodos e composições para o tratamento de cancro | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| IL256836B (en) | Methods for treating cancer using apilimod | |
| IL255022A0 (en) | Cancer treatment methods | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| EP4306173A3 (en) | Compositions and methods for treating cancers | |
| IL255018A0 (en) | Cancer treatment methods | |
| ZA201707024B (en) | Cancer treatment composition | |
| IL255016A0 (en) | Cancer treatment methods | |
| IL272782A (en) | Preparations and methods for the treatment of cancer | |
| IL256763A (en) | Compositions and methods for treating cancer | |
| ZA201802268B (en) | Methods and compositions for preventing or treating cancer | |
| EP3268028A4 (en) | Compositions and methods for treating cancer | |
| ZA201904626B (en) | Cancer treatment method and composition |